Cargando…
Validation and Implementation of a Highly Sensitive and Efficient Newborn Screening Assay for Mucopolysaccharidosis Type II
Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome, is a lysosomal storage disorder (LSD) caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS). MPS II satisfies all criteria defined by the Advisory Committee on Heritable Disorders in Newborns and Children (AC...
Autores principales: | Bilyeu, Heather, Washburn, Jon, Vermette, Lacey, Klug, Tracy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711921/ https://www.ncbi.nlm.nih.gov/pubmed/33124617 http://dx.doi.org/10.3390/ijns6040079 |
Ejemplares similares
-
Newborn Screening for Mucopolysaccharidosis Type II in Illinois: An Update
por: Burton, Barbara K., et al.
Publicado: (2020) -
Harmonization of Newborn Screening Results for Pompe Disease and Mucopolysaccharidosis Type I
por: Dorley, M. Christine, et al.
Publicado: (2023) -
Lessons Learned from Pompe Disease Newborn Screening and Follow-up
por: Klug, Tracy L., et al.
Publicado: (2020) -
Improved Reagents for Newborn Screening of Mucopolysaccharidosis
Types I, II, and VI by Tandem Mass Spectrometry
por: Chennamaneni, Naveen Kumar, et al.
Publicado: (2014) -
Newborn Screening Program for Mucopolysaccharidosis Type II and Long-Term Follow-Up of the Screen-Positive Subjects in Taiwan
por: Lin, Hsiang-Yu, et al.
Publicado: (2022)